DDInter1397 DDInter1492
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Paroxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Paroxetine {u} (Compound) downregulates {v} (Gene) PAFAH1B3
PAFAH1B3 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Paroxetine {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Paroxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ponatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) NFATC4
NFATC4 {u} (Gene) is regulated by {v} (Gene) HAL
HAL {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) interacts with {v} (Gene) FLT3
FLT3 {u} (Gene) is bound by {v} (Compound) Ponatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) regulates {v} (Gene) SSBP2
SSBP2 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Paroxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Paroxetine (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Ponatinib (Compound)
Paroxetine (Compound) downregulates PAFAH1B3 (Gene) and PAFAH1B3 (Gene) is downregulated by Ponatinib (Compound)
Paroxetine (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Ponatinib (Compound)
Paroxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Paroxetine (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound)
Paroxetine (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Paroxetine (Compound) upregulates NFATC4 (Gene) and NFATC4 (Gene) is regulated by HAL (Gene) and HAL (Gene) is upregulated by Ponatinib (Compound)
Paroxetine (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) interacts with FLT3 (Gene) and FLT3 (Gene) is bound by Ponatinib (Compound)
Paroxetine (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) regulates SSBP2 (Gene) and SSBP2 (Gene) is upregulated by Ponatinib (Compound)